Trials / Terminated
TerminatedNCT03151772
Bioavailability of Disulfiram and Metformin in Glioblastomas
Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Sahlgrenska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Neuro-oncological trials may fail due to the drug never getting to the intended target (i.e. within the tumor micro environment). Also, changes' occurring in tumor cells when removed from patients and grown in-vitro is another limiting factor influencing the clinical success. Important questions are therefore: 1. Does the drug get there? 2. Does the drug do what it is intended to do? To improve chances of clinical success there is a need for rational and intelligent selection of potential drugs in future trials. This is an initiative for analyzing tumor concentration of preoperative administered repurposed drugs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Disulfiram | 200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively |
| DRUG | Metformin | Metformin 850 mg x 3 taken preoperatively |
Timeline
- Start date
- 2018-01-29
- Primary completion
- 2020-09-24
- Completion
- 2020-09-24
- First posted
- 2017-05-12
- Last updated
- 2020-09-28
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03151772. Inclusion in this directory is not an endorsement.